Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Worm Research May Lead to Anti-Cancer Target

By R&D Editors | November 11, 2009

Researchers at Queen’s University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.

“When cancer hijacks a healthy system, it can create tumors by causing cells to divide when they shouldn’t,” says Ian Chin-Sang, a developmental biologist at Queen’s and lead researcher on the study. “Certain genes control the normal movement and growth of cells, and by studying how these genes interact, we can understand what is abnormal when cancer is present.”

There is an important gene in humans called PTEN that acts as a tumor suppressor. When the PTEN gene function is lost, it can lead to cancers. For example, 70-80 per cent of all prostate cancers have lost PTEN function. Another gene family, called Eph receptors, often shows high levels in cancers, but a connection between PTEN and Eph Receptors in cancer formation has never been shown. The Queen’s study shows the remarkable relationship between these genes in worms.

When the research team increased Eph receptor levels in worms, the PTEN levels diminished and the worms died prematurely. When they decreased the Eph receptor level in the worm, the PTEN levels went up and the worm lived longer than normal. The team believes the same principals are applicable to humans.

“Obviously humans and worms look very different,” states Professor Chin-Sang, “but at a molecular level, they are very similar. In some instances, like the ones we are studying, the cellular mechanisms are so similar that the human genes can replace the worm’s gene.”

The next step is to take a closer look at the interaction of these two genes in humans. The findings could lead to exciting breakthroughs in cancer treatment.

“There is a drug used in the treatment of breast cancer that some women develop a resistance to,” adds Professor Chin-Sang. “Those same women have also lost their PTEN. Perhaps their Eph is overactive, and that has made the PTEN go down. The research on the worm may therefore provide a useful drug target for therapeutic intervention of breast cancer. In fact, this worm is becoming a bit of a scientific celebrity. Studies on this worm have won researchers three Nobel prizes in the last seven years.”

Date: November 11, 2009
Source: Queen’s University 

Related Articles Read More >

Two RFD4-Proteina-designed enzymes that break down the pesticide paraoxon, with their structural accuracy and catalytic efficiency.
NVIDIA and UW’s protein design model produces 158 binders from 188 designs
Schematic of a whole-brain Perturb-seq atlas split into 1,946 perturbation profiles, each analyzed by its own AI agent.
OpenAI deploys nearly 2,000 GPT-Rosalind agents to generate biological research leads in 32 minutes
Surgical team operating under overhead lights in a modern operating room
Why promising technologies stall on the path to market: Lessons from medtech
UK Sovereign AI grant helps fund immune profiling of 80,000 UK Biobank blood samples
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE